Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.
Oncogénétique, Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France.
Fam Cancer. 2019 Apr;18(2):173-178. doi: 10.1007/s10689-018-0102-6.
Germline mutations of the POLE gene are responsible for polymerase proofreading-associated polyposis syndrome (PPAP). These mutations were hypothesised to predispose to extra-gastrointestinal tumours (ovary, endometrium, brain), but this association has not been confirmed so far. We report a family with an autosomal dominant inheritance of PPAP due to a c.1089C>A; p.Asn363Lys mutation in the proofreading exonuclease domain of POLE. Ten patients presenting a history of colorectal tumours and three patients with polyposis are indexed in this family. Three carriers (including siblings and a distant cousin at 30, 45 and 52 respectively) and another member (at 37 not tested) presented glioblastoma. This is the second family reported to carry this mutation. Among the four glioblastomas in the family that we report, both show similar pathology: giant cell glioblastoma. These cases suggest that the c.1089C>A germline POLE mutation may confer an increased risk of brain cancer [incidence 17.4% (4/23) in mutation carriers combining the two families]. More observations are needed to support this hypothesis. It seems that not all mutations of POLE are equally associated with extra-gastrointestinal tumours. Although carriers of a mutation responsible for PPAP should benefit from screening for colorectal and uterine cancer, due to the rapid evolution of glioblastoma the value of neurological follow-up and brain imaging screening remains questionable. Nevertheless, considering the limitations of standard therapy for glioblastoma, mutation status could be useful for targeting therapy. The biological mechanism linking POLE mutation to glioblastoma remains to be determined.
POLE 基因的种系突变导致聚合酶校对相关息肉病综合征 (PPAP)。这些突变被假设会导致胃肠道外肿瘤(卵巢、子宫内膜、脑),但到目前为止,这种关联尚未得到证实。我们报告了一个家族,该家族存在 POLE 外切核酸酶结构域中 c.1089C>A;p.Asn363Lys 突变,导致 PPAP 呈常染色体显性遗传。该家族中有 10 名患者有结直肠肿瘤病史,3 名患者有多发性息肉。3 名携带者(包括兄弟姐妹和 1 名 30、45 和 52 岁的远房表亲)和另一名成员(37 岁未接受测试)患有胶质母细胞瘤。这是第二个报道携带这种突变的家族。在我们报告的家族中的 4 例胶质母细胞瘤中,两者均显示出相似的病理学:巨细胞胶质母细胞瘤。这些病例表明,c.1089C>A 种系 POLE 突变可能会增加患脑癌的风险[两个家族的突变携带者发病率为 17.4%(4/23)]。需要更多的观察来支持这一假设。似乎并非 POLE 的所有突变都与胃肠道外肿瘤同等相关。尽管携带导致 PPAP 的突变的携带者应该受益于结直肠癌和子宫癌的筛查,但由于胶质母细胞瘤的快速演变,神经随访和脑部成像筛查的价值仍存在疑问。尽管如此,考虑到胶质母细胞瘤标准治疗的局限性,突变状态可能对靶向治疗有用。将 POLE 突变与胶质母细胞瘤联系起来的生物学机制仍有待确定。